Streetbeat News

Analyst Ratings

WEC

Mizuho analyst Anthony Crowdell has reiterated a 'Buy' rating on WEC Energy Group (NYSE:WEC) and maintained a price target of $98.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 12:41 pm

TRGP

Mizuho analyst Gabriel Moreen has reiterated a 'Buy' rating on Targa Resources (NYSE:TRGP) and maintained a price target of $99.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 12:41 pm

EQT

Wells Fargo analyst Roger Read has maintained an Overweight rating on EQT (NYSE:EQT) and raised the price target from $39 to $46.

Portfolio Pulse from Benzinga Newsdesk

June 30, 2023 | 12:41 pm

CPE

Mizuho analyst Nitin Kumar maintains a 'Buy' rating on Callon Petroleum (NYSE:CPE) and raises the price target from $54 to $59.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 12:39 pm

LBRT

Wells Fargo analyst Roger Read has maintained an Overweight rating on Liberty Energy (NYSE:LBRT) but lowered the price target from $24 to $21.

Portfolio Pulse from Benzinga Newsdesk

June 30, 2023 | 12:39 pm

SMPL

Mizuho analyst John Baumgartner has maintained a 'Buy' rating on Simply Good Foods (NASDAQ:SMPL), but lowered the price target from $45 to $42.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 12:38 pm

RNLX

TOP

XPEV

Renalytix AI (RNLX) received FDA approval for KidneyIntelX.dkd, a tool to assess kidney function risk in diabetic adults. TOP Financial reported a decrease in FY23 EPS to $0.10 from $0.12, but a 24% increase in total revenues to $9.7M. XPeng (XPEV) was upgraded to 'Outperform' by CLSA, with a raised price target of $13.1.

Portfolio Pulse from Benzinga Newsdesk

June 30, 2023 | 12:37 pm

NKE

RBC Capital analyst Piral Dadhania maintains an Outperform rating on Nike (NYSE:NKE) but has lowered the price target from $138 to $134.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 12:36 pm

JACK

RBC Capital analyst Christopher Carril maintains an Outperform rating on Jack In The Box (NASDAQ:JACK) and raises the price target from $96 to $110.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 12:35 pm

NBIX

RBC Capital analyst Brian Abrahams has reiterated a 'Sector Perform' rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a price target of $108.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 12:34 pm